Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 4.

Coens, Corneel; Suciu, Stefan; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Celeste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bottomley, Andrew; Kotapati, Srividya; de Pril, Veerle; Testori, Alessandro; Eggermont, Alexander M M (2017). Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. Lancet Oncology, 18(3):393-403.

Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Bastholt, Lars; Mortier, Laurent; Thomas, Luc; Tahir, Saad; Hauschild, Axel; Hassel, Jessica C; Hodi, F Stephen; Taitt, Corina; de Pril, Veerle; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2016). Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine, 375(19):1845-1855.

Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques; Dummer, Reinhard; Wolchok, Jedd D; Schmidt, Henrik; Hamid, Omid; Robert, Caroline; Ascierto, Paolo A; Richards, Jon M; Lebbé, Céleste; Ferraresi, Virginia; Smylie, Michael; Weber, Jeffrey S; Maio, Michele; Konto, Cyril; Hoos, Axel; de Pril, Veerle; Gurunath, Ravichandra Karra; de Schaetzen, Gaetan; Suciu, Stefan; Testori, Alessandro (2015). Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncology, 16(5):522-530.

Weber, Jeffrey S; Dummer, Reinhard; de Pril, Veerle; Lebbé, Celeste; Hodi, F Stephen (2013). Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer, 119(9):1675-1682.

This list was generated on Mon Dec 11 18:37:20 2017 CET.